Guangzhou DaAn Gene Co., Ltd. (002030.SZ) recently released an announcement regarding the progress of a change in its indirect controlling shareholder. Guangzhou Pharmaceutical Capital Co., Ltd., a wholly-owned subsidiary of Guangzhou Pharmaceutical Group, has signed formal transaction documents, including the “Agreement on the Acquisition of Control Rights of Guangzhou DaAn Gene Co., Ltd.,” with DaAn Gene’s shareholders: Guangzhou Financial Holding Group Co., Ltd., Guangzhou Biomedical and Health Industry Investment Co., Ltd., and Guangzhou Guangyong Technology Development Co., Ltd.

According to the acquisition agreement, Guangzhou Pharmaceutical Capital will acquire 100% equity of Guangzhou Guangyong Technology from Guangzhou Financial Holding, thereby indirectly controlling 233,391,995 shares of DaAn Gene held by Guangyong Technology, representing 16.63% of DaAn Gene’s total share capital. Additionally, through a separate agreement, Guangzhou Pharmaceutical Capital will acquire 70,172,302 shares of DaAn Gene from Guangzhou Financial Holding, representing 5% of the total share capital, and 70,172,304 shares from Guangzhou Health Industry Investment, representing another 5% of the total share capital. After the acquisition is completed, Guangzhou Pharmaceutical Capital will become the indirect controlling shareholder of DaAn Gene, controlling a total of 373,736,601 shares, or 26.63% of the total share capital.

DaAn Gene is a leading provider of in vitro diagnostic solutions, specializing in molecular diagnostics. The company integrates the research, development, production, and sales of clinical testing reagents, instruments, and related consumables, and is recognized as one of the most technologically advanced and comprehensive in vitro diagnostic enterprises in China.

Guangzhou Pharmaceutical Capital is the core capital platform for the strategic development of Guangzhou Pharmaceutical Group. Through this acquisition, the group will add another controlled listed company, helping to optimize its industrial layout. As a result, Guangzhou Pharmaceutical Group’s controlled and strategically invested listed companies now include Baiyunshan, Kangmei Pharmaceutical, Nanjing Pharmaceutical, and DaAn Gene.

Analysts suggest that taking control of DaAn Gene represents a key move for Guangzhou Pharmaceutical Group in the diagnostic equipment sector, potentially elevating the group into the top tier of the domestic in vitro diagnostic field. At the same time, DaAn Gene can leverage Guangzhou Pharmaceutical Group’s advantages in pharmaceutical distribution and research platforms to achieve breakthroughs in market promotion, new product development, and new technology innovation.

Baiyunshan

Baiyunshan, or White Cloud Mountain, is a famous scenic area in Guangzhou, China, known for its lush greenery, peaks, and panoramic city views. Its history dates back over a thousand years, serving as a retreat for scholars and Taoist practitioners during the Jin and Tang dynasties. Today, it remains a popular destination for hiking and cultural exploration, featuring historic temples and pavilions.

Kangmei Pharmaceutical

Kangmei Pharmaceutical is a major Chinese pharmaceutical company known for its involvement in traditional Chinese medicine (TCM) production and distribution. Founded in 1997 and headquartered in Guangdong, the company grew rapidly before becoming embroiled in a high-profile financial scandal in 2018, which involved massive accounting fraud. This led to significant legal consequences, including fines and leadership changes, highlighting issues of corporate governance in China’s pharmaceutical industry.

Nanjing Pharmaceutical

Nanjing Pharmaceutical, officially known as Nanjing Pharmaceutical Co., Ltd., is one of China’s oldest and largest pharmaceutical companies, with a history dating back to its founding in 1933. Originally established as a state-owned enterprise, it has played a key role in the development of China’s modern pharmaceutical industry, particularly in the production of traditional Chinese medicine and Western drugs. Today, the company is a

Baiyunshan

Baiyunshan, also known as White Cloud Mountain, is a famous scenic area in Guangzhou, China, consisting of a range of hills and lush forests. Its history dates back over 1,200 years to the Tang Dynasty, when it became a popular retreat for poets and scholars, and later developed into a renowned Taoist site with temples and pavilions. Today, it is a major urban park and a symbol of the city, offering hiking trails and panoramic views of Guangzhou.

Related news

Apologies from Xibei: Nine Adjustments to Be Implemented, Multiple Dishes to Be Freshly Prepared and Cooked.
On September 15, Xibei issued an official apology ...

China responds to reports of Nvidia chip purchase ban on companies like Alibaba.
Beijing, September 18 — Chinese Foreign Ministry S...

Artificial straw checkerboard barriers are being laid in the core area of the Horqin Sandy Land to stabilize the sand.
1/5 On April 23, within the comprehensive manageme...

UN concerned about Ebola outbreak spreading in Africa, warns it may worsen food shortages.
The Ebola outbreak in the Democratic Republic of t...

ASEAN Research Trip｜Hands-On Experience: Achieving “Mobile Phone Freedom” in Malaysia
From morning till night, Kuala Lumpur Internationa...